Structural Elucidation of β_1 - and β_2 -Transferrin Using Microprobe-Capture In-Emitter Elution and High-Resolution Mass Spectrometry

Ruben Yiqi Luo^{1,2}, Christopher Pfaffroth², Samuel Yang¹, Kevin Hoang², Priscilla S.-W.

Yeung^{1,2}, James L. Zehnder^{1,2}, Run-Zhang Shi^{1,2}

¹Department of Pathology, Stanford University, Stanford, CA, USA

²Clinical Laboratories, Stanford Health Care, Palo Alto, CA, USA

Running Title: Structural Elucidation of β_1 - and β_2 -Tf Using MPIE and HR-MS

Corresponding Author: Ruben Yiqi Luo

Address: 3375 Hillview Ave, Palo Alto, CA 94304

Tel: 650-724-1318

Email: rubenluo@stanford.edu

Key Words: β_1 -Transferrin, β_2 -Transferrin, MPIE-ESI-MS, N-Glycan

1 Abstract

2

Z	
3	Background: Cerebrospinal fluid (CSF) leak is typically diagnosed by detecting a protein marker
4	β_2 -transferrin (β_2 -Tf) in secretion samples. β_2 -Tf and β_1 -transferrin (β_1 -Tf) are glycoforms of
5	human transferrin (Tf). A novel affinity capture technique for sample preparation, called
6	microprobe-capture in-emitter elution (MPIE), was incorporated with high-resolution mass
7	spectrometry (HR-MS) to analyze the Tf glycoforms and elucidate the structures of β_1 -Tf and β_2 -
8	Tf.
9	Methods: To implement MPIE, an analyte is first captured on the surface of a microprobe, and
10	subsequently eluted from the microprobe inside an electrospray emitter. The capture process is
11	monitored in real-time via next-generation biolayer interferometry (BLI). When electrospray is
12	established from the emitter to a mass spectrometer, the analyte is immediately ionized via
13	electrospray ionization (ESI) for HR-MS analysis. Serum, CSF, and secretion samples were
14	analyzed using MPIE-ESI-MS.
15	Results: Based on the MPIE-ESI-MS results, the structures of β_1 -Tf and β_2 -Tf were solved. As Tf
16	glycoforms, β_1 -Tf and β_2 -Tf share the amino acid sequence but have varying N-glycans. β_1 -Tf,
17	the major serum-type Tf, has two G2S2 N-glycans on Asn413 and Asn611. β_2 -Tf, the major
18	brain-type Tf, has an M5 N-glycan on Asn413 and a G0FB N-glycan on Asn611.
19	Conclusions: The structures of β_1 -Tf and β_2 -Tf were successfully elucidated by MPIE-ESI-MS
20	analysis. The resolving power of the novel MPIE-ESI-MS method was demonstrated in this
21	study. On the other hand, knowing the N-glycan structures on β_2 -Tf allows for the design of
22	other novel test methods for β_2 -Tf in the future.
22	

24 Introduction

26	Cerebrospinal fluid (CSF) leak can occur as a result of laceration, blunt trauma, or surgery. It
27	may lead to potentially life-threatening meningitis if left untreated (1,2). Because β_2 -transferrin
28	(β_2 -Tf), a proteoform of human transferrin (Tf), is mainly present in CSF and barely detectable in
29	other body fluids (3,4), CSF leak can be diagnosed by detecting β_2 -Tf in any body fluid – most
30	commonly in rhinorrhea or otorrhea secretion samples. The clinical utility and diagnostic value
31	of β_2 -Tf in CSF leak have been demonstrated (5,6). β_2 -Tf, together with the typical Tf
32	proteoform in serum β_1 -transferrin (β_1 -Tf), were named after their electrophoretic mobility in gel
33	electrophoresis (7). However, the structures of β_1 -Tf and β_2 -Tf have not been elucidated.
34	
35	There has been extensive basic research on human Tf since it is a high-abundance protein in
36	human blood with a major role in iron metabolism. The amino acid sequence of Tf precursor was
37	determined through protein cleavage and cDNA characterization, showing a full sequence of 698
38	amino acids; after the removal of an N-terminal signal peptide, the mature form of Tf contains
39	679 amino acids, 19 intramolecular disulfide bonds formed between cysteine residues, and two
40	N-glycans attached to the amino groups of the side chains of Asn419 and Asn611 (Asn432 and
41	Asn630 of Tf precursor) (8–11). Tf proteoforms typically vary by the N-glycan structures (11–
42	13), and the Tf proteoforms of interest so far are Tf glycoforms, including β_1 -Tf and β_2 -Tf (7).
43	
44	Although it is known that β_2 -Tf has desialylated N-glycans while β_1 -Tf has fully sialylated N-
45	glycans (3,14,15), the structures of β_1 -Tf and β_2 -Tf have not been clarified. On the other hand,
46	the N-glycans on Tf glycoforms in serum and in CSF were characterized using gel

47	electrophoresis, liquid chromatography, and enzymatic digestion-based mass spectrometry (MS)
48	by neurobiologists (13,16–19). It was reported that a group of Tf glycoforms were present in
49	serum, namely serum-type Tf or sTf, among which a specific Tf glycoform (major serum-type
50	Tf) predominated (12,13); the serum-type Tf also existed in CSF, and the major serum-type Tf
51	used to be named Tf-2 in CSF (18); an additional group of Tf glycoforms were present in CSF,
52	namely brain-type Tf or Tf-1 in CSF, among which a specific Tf glycoform (major brain-type
53	Tf) was more abundant than the rest (15,20). The brain-type Tf was at least partly synthesized in
54	the CSF-producing tissue choroid plexus rather than being produced by glycosidase digestion of
55	serum-type Tf (16,20). It was found that the N-glycans on the major serum-type Tf consisted of
56	bi-antennary oligosaccharide chains with sialylated terminals, and those on the brain-type Tf are
57	desialylated, or more specifically, unsialylated (asialotransferrin) (15,16,18,20). It was
58	hypothesized that the major brain-type Tf was β_2 -Tf (21), but this hypothesis has not been
59	proved.

60

In clinical cases where CSF leak is suspected, secretion samples can be collected from patients and sent to clinical laboratories to test for the presence of β_2 -Tf. The conventional method to test β_2 -Tf as well as β_1 -Tf is agarose gel immunofixation electrophoresis (IFE) (2–4). Although it is widely used in clinical laboratories, it does not provide structural information of the analytes. Thus, the structures of β_1 -Tf and β_2 -Tf, particularly the N-glycan structures on these Tf glycoforms, remained an unanswered question with this method.

67

As an emerging technology in clinical diagnostics, high-resolution mass spectrometry (HR-MS),

69 particularly top-down HR-MS, can be used to analyze a protein target in its intact state and

70 elucidate the post-translational modifications and amino acid variations in its proteoforms (22– 71 24). While HR-MS is an ideal tool to analyze the Tf glycoforms, the quality of data acquired 72 during HR-MS analysis depends on sample preparation (25,26). In this article, a novel affinity 73 capture technique for sample preparation, called microprobe-capture in-emitter elution (MPIE), was incorporated with HR-MS to study the Tf glycoforms (27). MPIE can directly couple a 74 75 label-free optical sensing technology with MS. The label-free optical sensing technology is next-76 generation biolayer interferometry (BLI, also named as thin-layer interferometry, TFI), which 77 senses optical thickness changes on the sensing surface of a microprobe caused by biomolecular 78 interactions, achieving real-time measurement without employing a reporter molecule (enzyme, 79 fluorophore, etc.) (28,29). To implement MPIE, an analyte is first captured on the surface of a microprobe, and subsequently eluted from the microprobe inside an electrospray emitter. The 80 81 capture process is monitored in real-time via BLI. When electrospray is established from the 82 emitter to a mass spectrometer, the analyte is immediately ionized via electrospray ionization 83 (ESI) for HR-MS analysis. By this means, BLI and HR-MS are directly coupled in the form of 84 MPIE-ESI-MS, which is readily deployed to analyze the Tf glycoforms and elucidate the 85 structures of β_1 -Tf and β_2 -Tf. The study can pave a way for the development of novel clinical assays for β_2 -Tf. 86

87

88 Materials and Methods

89

90 <u>Materials and Specimens</u>

92	LC-MS grade water, acetonitrile, formic acid, and $0.2 \mu m$ PVDF syringe filters were purchased
93	from Thermo Fisher Scientific (Waltham, MA). Tf standard (purified sTf) was purchased from
94	Sigma-Aldrich (St. Louis, MI). A mouse monoclonal anti-transferrin IgG antibody (anti-Tf Ab)
95	was obtained from Sinobiological (Wayne, PA), and biotinylated using an EZ-Link HPDP-Biotin
96	reagent kit (Waltham, MA). Remnant CSF and serum samples from patients, and secretion
97	samples from patients suspected of CSF leak were obtained from Stanford Health Care and
98	Stanford Children's Health, following approved institutional review board protocols for the use
99	of remnant patient specimens.
100	
101	Sample Preparation
102	
103	The biotinylated anti-Tf Ab was diluted in phosphate-buffered saline at pH 7.4 with 0.02%
104	Tween 20 and 0.2% BSA (PBST-B) to 10 $\mu g/ml$ for use. A pooled CSF sample was made by
105	mixing 9 CSF samples from patients to explore the analytical sensitivity of MPIE-ESI-MS for
106	β_2 -Tf in CSF. The pooled CSF sample was mixed with water to make a dilution series. All CSF
107	samples were 1:1 diluted in phosphate-buffered saline at pH 7.4 with 0.02% Tween 20 (PBST)
108	and all serum samples were 1:19 diluted in PBST-B. Secretion samples from patients were first
109	mixed with an equal amount of water and filtered using a 0.2 μ m PVDF syringe filter, and then
110	1:1 diluted in PBST.
111	
112	To study the gel electrophoresis-separated Tf glycoforms, gel electrophoresis of CSF samples
113	was carried out using a Hydragel 6 β_2 Transferrin kit (Sebia, Lisses, France) following the
114	manufacturer's protocol. In brief, a CSF sample was first 1:1 mixed with an iron-saturating

115	solution, and then 10 μl of the sample was loaded to each of the 6 wells on an agarose gel. Gel
116	electrophoresis was implemented in a Hydrasys 2 instrument (Sebia, Lisses, France), and the
117	agarose gel was removed from the instrument after the gel electrophoresis was completed,
118	without running the immunofixation steps. The agarose gel was placed on a paper template
119	marked with the β_1 -Tf and β_2 -Tf band regions, and the gel stripes of the band regions were cut
120	out using a scalpel. Each gel stripe was placed in a 1.5 ml sample tube, 200 μ l PBST was added,
121	and the sample was rocked for 2 hr at room temperature to extract the analyte from the gel stripe.
122	After extraction, the supernatant was filtered using a 0.2 μ m PVDF syringe filter.
123	
124	MPIE-ESI-MS Instrumentation and Experiment
125	
126	An MPIE-ESI-MS experiment consists of two parts: BLI-based affinity capture and in-emitter
127	elution ESI-MS, with the details including instrumentation described elsewhere (27). The BLI-
128	based affinity capture was implemented in a Gator Plus analyzer (Gator Bio, Palo Alto, CA): a
129	BLI microprobe pre-coated with streptavidin was first dipped into the biotinylated anti-Tf Ab
130	solution for 10 min to load the anti-Tf Ab, then dipped into a sample for 10 min to capture Tf
131	molecules, and rinsed in PBST for 1 min to remove non-specifically bound molecules. The in-
132	emitter elution ESI-MS was implemented in an EMASS-II ESI ion source which coupled an
133	ECE-001 capillary electrophoresis instrument (CMP Scientific, Brooklyn, NY) with an Orbitrap
134	Q-Exactive Plus mass spectrometer (Thermo Scientific, San Jose, CA): an electrospray emitter
135	with a regular open end and a tapered open end (tip orifice diameter 20-30 μ m) was filled with a

rinsed in the sheath liquid for 10 s, inserted into the emitter through the regular open end, and

136

sheath liquid (10 mM ammonium formate in water); after affinity capture, the microprobe was

138	settled in the tapered end by gravity; the emitter was mounted to the ESI ion source, and a
139	capillary was inserted into the emitter through the regular open end and positioned right behind
140	the microprobe to deliver an elution liquid (80% acetonitrile and 2% formic acid in water); once
141	electrospray was established by applying a positive voltage to the sheath liquid in the emitter,
142	HR-MS data acquisition was initiated, and injection of the elution liquid was started
143	subsequently. The emitter was placed $\sim 2 \text{ mm}$ away from the mass spectrometer inlet with the
144	electrospray voltage set at 2.2 kV. The injection of the elution liquid was driven by 5 psi
145	pneumatic pressure. The following MS parameters were used: ion-transfer capillary temperature
146	350°C, S-lens RF level 50, and number of microscans 10. Primary mass spectra were acquired in
147	positive polarity at resolution 17.5K.
148	
149	Data Analysis
150	
151	In HR-MS analysis of proteins, it is necessary to deconvolute raw MS data to merge the multiple
152	charge states and isotopic peaks of an analyte to obtain its accurate molecular mass. The acquired
153	data in each MPIE-ESI-MS experiment was viewed as a time trace of MS responses, and the
154	elution time window of an analyte was identified by checking the molecular ions of the analyte at
155	each time point. The data in the elution time window were selected for deconvolution using
156	Biopharma Finder 4.1 (Thermo Fisher Scientific, San Jose, CA) with the ReSpect algorithm. MS
157	peaks of analytes were displayed in deconvoluted mass spectra at uncharged state showing
158	average molecular masses.

159

160 **Results**

161

The performance of MPIE-ESI-MS for Tf analysis was demonstrated and reported elsewhere 162 (27). MPIE-ESI-MS had a limit of detection for the Tf standard at 0.063 µg/ml, which was 163 164 translated to no more than 7 fmol Tf molecules captured on a microprobe (27). The high analytical sensitivity and specificity provided by affinity capture made MPIE-ESI-MS an ideal 165 method to study the Tf molecules in serum, CSF, and secretion samples. The results of a set of 166 samples are shown in Figure 1. The deconvoluted mass spectrum of the serum sample showed a 167 group of MS peaks around 79554 Da; they are mainly serum-type Tf glycoforms and the 168 169 predominant MS peak at 79554 Da should be the major serum-type Tf (N-glycan structures 170 shown in Figure 1, see details in Discussion). The deconvoluted mass spectrum of the CSF sample showed the major serum-type Tf and a group of MS peaks around 78008 Da; they are 171 172 mainly brain-type Tf glycoforms and the most abundant MS peak at 78008 Da should be the major brain-type Tf (N-glycan structures shown in Figure 1, see details in Discussion). The 173 174 deconvoluted mass spectrum of the secretion sample showed both serum-type Tf and brain-type 175 Tf glycoforms, meaning that CSF was present in the sample. This finding was consistent with the fact that the secretion sample was obtained from a patient diagnosed of CSF leak. In addition, the 176 177 BLI sensorgram (a time trace of label-free optical sensing responses) of each affinity capture process (capture of Tf by anti-Tf Ab on a microprobe) is shown in Figure S1, allowing for real-178 time monitoring of the capture process. 179

180

181 To elucidate the structures of the Tf glycoforms β_1 -Tf and β_2 -Tf, after gel electrophoresis of CSF 182 samples, the extracts from the gel stripes of the β_1 -Tf and β_2 -Tf band regions were analyzed 183 using MPIE-ESI-MS. The results of a set of samples are shown in Figure 2. The deconvoluted

184	mass spectra showed the MS peak of only the major serum-type Tf in the extract from the β_1 -Tf
185	band region and the MS peak of only the major brain-type Tf in the extract from the β_2 -Tf band
186	region. The measured accurate molecular masses were consistent with the experiments in Figure
187	1 and matched the theoretical molecular masses of the major serum-type Tf and major brain-type
188	Tf (N-glycan structures shown in Figure 2, see details in Discussion). This observation
189	confirmed that β_1 -Tf and β_2 -Tf were actually the major serum-type Tf and major brain-type Tf,
190	respectively. In addition, the gel area between the β_1 -Tf and β_2 -Tf band regions was also
191	analyzed and minor Tf glycoforms in serum and CSF were found, which could be due to the low
192	abundance of the minor Tf glycoforms and limited analyte quantities in a gel stripe.
193	
194	A set of 12 secretion samples from patients suspected of CSF leak were analyzed using the
195	MPIE-ESI-MS method, among which 5 samples were positive for β_2 -Tf and the rest were
196	negative as measured by IFE test and clinical manifestations. As shown in Table 1, the MS peak
197	at 78008 Da was observed in the MPIE-ESI-MS results of the 5 positive samples but not found
198	in those of the 7 negative samples, which further verified that β_2 -Tf was indeed the major brain-
199	type Tf. In addition, the analytical sensitivity of the MPIE-ESI-MS method for CSF and
200	secretion samples was explored. A pooled CSF sample was mixed with water at 1:1, 1:4, 1:9, and
201	1:19 ratios to prepare a dilution series for analysis. Table S1 summarizes the results, listing the
202	MS peak intensities of β_1 -Tf and β_2 -Tf in the deconvoluted mass spectra (the entire time window
203	of Tf elution selected for deconvolution). The peak intensities decreased with the pooled CSF
204	sample dilution, and it was demonstrated that the MPIE-ESI-MS method was able to detect β_2 -Tf
205	in at least 10-fold diluted CSF (1:9 pooled CSF : water mixture).

207 Discussion

209	The amino acid sequence of Tf was previously reported (8,9) and the primary structure of a
210	mature Tf molecule is illustrated in Figure 3A. As Tf glycoforms, β_1 -Tf and β_2 -Tf share the
211	amino acid backbone but have varying N-glycans. The N-glycans on proteins typically include
212	bi-, tri-, or tetra-antennary oligosaccharide chains, resulted from sequential action of
213	glycosyltransferases (30,31). An N-glycan can be named according to its sugar composition and
214	branching structure using a few nomenclature systems (traditional nomenclature used in this
215	article) (32). With designated N-glycan types, the accurate molecular mass of a Tf glycoform can
216	be calculated, and the correctness of the N-glycan types can be confirmed by comparing the
217	theoretical molecular mass of the Tf glycoform to the measured accurate molecular mass.
218	
219	Regarding the N-glycans on Tf, the previous enzymatic digestion-based MS analysis of the Tf
220	glycoforms in CSF revealed explicitly that the most abundant N-glycan type was G2S2 (17,19).
221	By measuring the trypsin-digested peptides encompassing the glycosylation sites, G2S2 was
222	found consisting of roughly 65% of all N-glycans on Asn413 and 73% of all N-glycans on
223	Asn611 (17). Thus, the Tf glycoform with two G2S2 N-glycans on Asn413 and Asn611 is the
224	major serum-type Tf because (1) it is the most abundant Tf glycoform in serum and CSF, (2) it is
225	fully sialylated (N-acetylneuraminic acid as the sialic acid), and (3) its theoretical molecular
226	mass 79554.71 Da exactly matches the measured molecular mass of the major serum-type Tf
227	(Figure 3B). As the second most abundant Tf glycoform and the most abundant unsialylated Tf
228	glycoform in CSF, the major brain-type Tf should be associated with N-glycan types M5 and
229	G0FB (Figure 3B), which were found as the most abundant unsialylated N-glycans (19).

230	Particularly, M5 was found consisting of roughly 20% of all N-glycans on Asn413 and G0FB
231	was found consisting of 26% of all N-glycans on Asn611 (17). Thus, the major brain-type Tf has
232	an M5 N-glycan on Asn413 and a G0FB N-glycan on Asn611. Its theoretical molecular mass
233	78008.35 Da exactly matches the measured molecular mass of the major brain-type Tf. The
234	glycosylation sites of the M5 and G0FB N-glycans were confirmed with another study of
235	trypsin-digested glycopeptides from Tf glycoforms in CSF (18). In addition, the presence of a
236	bisecting N-acetylglucosamine (GlcNAc) in the G0FB N-glycan was proved by the previously
237	reported lectin-binding experiments (16), supporting that G0FB is the more favorable N-glycan
238	type on Asn611 than the other isomeric N-glycan type without a bisecting GlcNAc (19). In
239	addition, the MPIE-ESI-MS analysis of the extracts from the gel bands proved that β_1 -Tf and the
240	major serum-type Tf were identical, so were β_2 -Tf and the major brain-type Tf.
241	
242	Besides the two major Tf glycoforms in CSF (β_1 -Tf and β_2 -Tf), it is known that other minor Tf
243	glycoforms may also exist in CSF, blood, and other body fluids (4,33). As illustrated in the
244	previous literature, there are a variety of unsialylated N-glycans on Tf molecules, and the
245	sialylated N-glycan G2S2 also has diversity such as the more branched form G3S3 (13,17,34).
246	Thus, a number of fully sialylated, partially sialylated, and unsialylated Tf glycoforms can be
247	formed by the various combinations of the two N-glycans on a Tf molecule. In gel
248	electrophoresis, sialic acids bring negative charges to a Tf molecule under neutral or alkaline pH
249	conditions, influencing its electrophoretic mobility. As such, Tf glycoforms migrate in the order
250	of fully sialylated, disialylated, and unsialylated Tf glycoforms, with regard to the number of
251	sialic acids on the N-glycans. Thus, the minor Tf glycoforms can migrate within or between the
252	β_1 -Tf and β_2 -Tf band regions. For instance, the product insert of the Hydragel 6 β_2 Transferrin kit

253 states that a band of disialylated Tf glycoforms (disialotransferrin) may exist above the β_2 -Tf 254 band (35). On the other hand, the unsialylated Tf glycoforms besides β_2 -Tf can migrate within the β_2 -Tf band region and interfere with the β_2 -Tf detection. The product insert suggests that the 255 256 ratio of unsialylated to disialylated bands can be used to confirm the presence of β_2 -Tf. The 257 reason of this practice can be explained as follows: when CSF is present in a sample, the abundance of the major unsialylated Tf glycoform β_2 -Tf significantly exceeds the minor 258 259 unsialylated and disialylated Tf glycoforms, resulting in a high ratio of the β_2 -Tf band to the 260 disialotransferrin band. This practice in IFE is derived from the lack of molecular structure information in gel electrophoresis. However, when MS is employed, such as in the use of MPIE-261 ESI-MS, it is unnecessary to compare unsialylated and disialylated Tf glycoforms because β_2 -Tf 262 can be specifically detected by its accurate molecular mass, definitively differentiating it from 263 264 the other Tf glycoforms with different molecular masses.

265

The demonstration of MPIE-ESI-MS in detection of β_2 -Tf paved a way to establish a MS-based 266 267 clinical assay for β_2 -Tf. However, more factors need to be taken into consideration for this purpose. When implementing the accurate molecular mass-based detection of β_2 -Tf, Tf variants 268 resulted from genetic polymorphism should be taken into consideration (11, 36-39). In theory, 269 270 the amino acid mutations in Tf variants affect the molecular masses of β_1 -Tf and β_2 -Tf, but they 271 should not change the molecular mass difference between the two Tf glycoforms (1546 Da), provided the two glycosylation sites are not modified. This hypothesis is supported by the MPIE-272 273 ESI-MS results of a few Tf variant-containing CSF samples, as shown in Figure S2, but it needs 274 to be proved with a larger number of Tf variant samples. In addition, the glycoforms in serum-275 type Tf can vary under specific pathophysiological conditions and β_1 -Tf might not be found in

276	those samples due to aberrant glycosylation (12,34). In such cases the detection and
277	identification of β_2 -Tf can be impacted. These topics are beyond the scope of this article and can
278	be investigated in the future when a MS-based clinical assay for β_2 -Tf is being developed.
279	
280	Conclusions
281	
282	The structures of β_1 -Tf and β_2 -Tf were successfully elucidated by MPIE-ESI-MS analysis. The
283	resolving power of the novel MPIE-ESI-MS method was demonstrated in this study. As an
284	innovative affinity capture technique, MPIE facilitates real-time monitoring of the affinity
285	capture process to overcome the lack of process monitoring in conventional affinity capture
286	techniques (27). On the other hand, knowing the N-glycan structures on β_2 -Tf allows for the
287	design of other novel test methods for β_2 -Tf in the future. For instance, it is possible to employ
288	carbohydrate-binding reagents to selectively capture β_2 -Tf for MS analysis or to establish
289	antibody-lectin Sandwich immunoassays.
290	
291	Acknowledgment
292	
293	The authors thank Gator Bio (Palo Alto, CA) and CMP Scientific (Brooklyn, NY) for kindly
294	providing equipment and consumables, and C. Wong, S. Ferolino, L. Calayag, and R. Rieta at
295	Stanford Health Care for collecting samples for this research.
296	
297	References
298	

- Warnecke A, Averbeck T, Wurster U, Harmening M, Lenarz T, Stöver T. Diagnostic
 Relevance of β2-Transferrin for the Detection of Cerebrospinal Fluid Fistulas. Arch
 Otolaryngol Neck Surg. 2004 Oct 1;130(10):1178.
- McCudden CR, Senior BA, Hainsworth S, Oliveira W, Silverman LM, Bruns DE, et al.
 Evaluation of high resolution gel β₂ -transferrin for detection of cerebrospinal fluid leak.
 Clin Chem Lab Med CCLM. 2013 Feb 1;51(2):311–5.
- Papadea C, Schlosser RJ. Rapid Method for β2-Transferrin in Cerebrospinal Fluid Leakage
 Using an Automated Immunofixation Electrophoresis System. Clin Chem. 2005 Feb
 1;51(2):464–70.
- Görögh T, Rudolph P, Meyer JE, Werner JA, Lippert BM, Maune S. Separation of β2-Transferrin by Denaturing Gel Electrophoresis to Detect Cerebrospinal Fluid in Ear and Nasal Fluids. Clin Chem. 2005 Sep 1;51(9):1704–10.
- Zaret DL, Morrison N, Gulbranson R, Keren DF. Immunofixation to Quantify β2-Transferrin
 in Cerebrospinal Fluid to Detect Leakage of Cerebrospinal Fluid from Skull Injury. Clin
 Chem. 1992 Sep 1;38(9):1909–12.
- Nandapalan V, Watson ID, Swift AC. Beta-2-transferrin and cerebrospinal fluid rhinorrhoea.
 Clin Otolaryngol. 1996 Jun;21(3):259–64.
- Gallo P, Bracco F, Morara S, Battistin L, Tavolato B. The cerebrospinal fluid transferrin/Tau proteins. J Neurol Sci. 1985 Aug;70(1):81–92.
- Yang F, Lum JB, McGill JR, Moore CM, Naylor SL, van Bragt PH, et al. Human transferrin:
 cDNA characterization and chromosomal localization. Proc Natl Acad Sci. 1984
 May;81(9):2752–6.
- MacGillivray RT, Mendez E, Sinha SK, Sutton MR, Lineback-Zins J, Brew K. The complete amino acid sequence of human serum transferrin. Proc Natl Acad Sci. 1982 Apr;79(8):2504– 8.
- Wang S, Kaltashov IA. Identification of Reduction-Susceptible Disulfide Bonds in
 Transferrin by Differential Alkylation Using O ¹⁶/O ¹⁸ Labeled Iodoacetic Acid. J Am Soc
 Mass Spectrom. 2015 May 1;26(5):800–7.
- 11. de Jong G, van Dijk JP, van Eijk HG. The biology of transferrin. Clin Chim Acta. 1990
 Sep;190(1-2):1-46.
- 12. de Jong G, van Eijk HG. Microheterogeneity of human serum transferrin: A biological
 phenomenon studied by isoelectric focusing in immobilized pH gradients. Electrophoresis.
 1988;9(9):589–98.
- 13. de Jong G, van Noort WL, van Eijk HG. Carbohydrate analysis of transferrin subfractions
 isolated by preparative isoelectric focusing in immobilized pH gradients. Electrophoresis.
 1992;13(1):225–8.

- 14. Delaroche O, Bordureb P, Lippert E, Sagnieza M. Perilymph detection by β2-transferrin
 immunoblotting assay. Application to the diagnosis of perilymphatic fistulae. Clin Chim
 Acta. 1996 Feb;245(1):93–104.
- 15. Hoffmann A, Nimtz M, Getzlaff R, Conradt HS. 'Brain-type' *N* -glycosylation of asialo transferrin from human cerebrospinal fluid. FEBS Lett. 1995 Feb 13;359(2–3):164–8.
- Futakawa S, Nara K, Miyajima M, Kuno A, Ito H, Kaji H, et al. A unique N-glycan on
 human transferrin in CSF: a possible biomarker for iNPH. Neurobiol Aging. 2012
 Aug;33(8):1807–15.
- 343 17. Brown KJ, Vanderver A, Hoffman EP, Schiffmann R, Hathout Y. Characterization of
 344 transferrin glycopeptide structures in human cerebrospinal fluid. Int J Mass Spectrom. 2012
 345 Feb;312:97–106.
- 18. Nagae M, Morita-Matsumoto K, Arai S, Wada I, Matsumoto Y, Saito K, et al. Structural
 change of N-glycan exposes hydrophobic surface of human transferrin. Glycobiology. 2014
 Aug 28;24(8):693–702.
- 19. Hoshi K, Ito H, Abe E, Fuwa TJ, Kanno M, Murakami Y, et al. Transferrin Biosynthesized
 in the Brain Is a Novel Biomarker for Alzheimer's Disease. Metabolites. 2021 Sep
 10;11(9):616.
- 20. Hoshi K, Matsumoto Y, Ito H, Saito K, Honda T, Yamaguchi Y, et al. A unique glycanisoform of transferrin in cerebrospinal fluid: A potential diagnostic marker for neurological
 diseases. Biochim Biophys Acta BBA Gen Subj. 2017 Oct;1861(10):2473–8.
- 21. Caslavska J, Schild C, Thormann W. High□resolution capillary zone electrophoresis and
 mass spectrometry for distinction of undersialylated and hypoglycosylated transferrin
 glycoforms in body fluids. J Sep Sci. 2020 Jan;43(1):241–57.
- 358 22. Siuti N, Kelleher NL. Decoding protein modifications using top-down mass spectrometry.
 359 Nat Methods. 2007 Oct;4(10):817–21.
- Brown KA, Melby JA, Roberts DS, Ge Y. Top-down proteomics: challenges, innovations,
 and applications in basic and clinical research. Expert Rev Proteomics. 2020 Oct
 2;17(10):719–33.
- 24. Luo RY, Wong C, Xia JQ, Glader BE, Shi RZ, Zehnder JL. Neutral-Coating Capillary
 Electrophoresis Coupled with High-Resolution Mass Spectrometry for Top-Down
 Identification of Hemoglobin Variants. Clin Chem. 2022 Oct 29;hvac171.
- 25. Donnelly DP, Rawlins CM, DeHart CJ, Fornelli L, Schachner LF, Lin Z, et al. Best practices
 and benchmarks for intact protein analysis for top-down mass spectrometry. Nat Methods.
 2019 Jul;16(7):587–94.

- Padula M, Berry I, O'Rourke M, Raymond B, Santos J, Djordjevic SP. A Comprehensive
 Guide for Performing Sample Preparation and Top-Down Protein Analysis. Proteomes. 2017
 Apr 7;5(4):11.
- 27. Luo RY, Yang S. Using Microprobe-Capture In-Emitter Elution to Directly Couple Label Free Optical Sensing Technology with Mass Spectrometry for Top-Down Protein Analysis
- [Internet]. Chemistry; 2022 Oct [cited 2022 Oct 25]. Available from:
- https://chemrxiv.org/engage/chemrxiv/article-details/6352339055a0816c28bee4cb
- 28. Luo YR, Chakraborty I, Lazar-Molnar E, Wu AHB, Lynch KL. Development of Label-Free
 Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and
 Antidrug Antibodies. Clin Chem. 2020 Oct 1;66(10):1319–28.
- 29. Luo YR, Yun C, Chakraborty I, Wu AHB, Lynch KL. A SARS-CoV-2 Label-Free Surrogate
 Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID19 Patients. Tang YW, editor. J Clin Microbiol [Internet]. 2021 Jun 18 [cited 2021 Nov
 4];59(7). Available from: https://journals.asm.org/doi/10.1128/JCM.00193-21
- 30. Bieberich E. Synthesis, Processing, and Function of N-glycans in N-glycoproteins. In: Yu
 RK, Schengrund CL, editors. Glycobiology of the Nervous System [Internet]. New York,
 NY: Springer New York; 2014 [cited 2021 Dec 6]. p. 47–70. (Advances in Neurobiology;
 vol. 9). Available from: http://link.springer.com/10.1007/978-1-4939-1154-7_3
- 387 31. Cao L, Diedrich JK, Ma Y, Wang N, Pauthner M, Park SKR, et al. Global site-specific
 388 analysis of glycoprotein N-glycan processing. Nat Protoc. 2018 Jun;13(6):1196–212.
- 389 32. Maier M, Reusch D, Bruggink C, Bulau P, Wuhrer M, Mølhøj M. Applying mini-bore
 390 HPAEC-MS/MS for the characterization and quantification of Fc N -glycans from
 391 heterogeneously glycosylated IgGs. J Chromatogr B. 2016 Oct;1033–1034:342–52.
- 392 33. Kleinert P, Kuster T, Durka S, Ballhausen D, Bosshard NU, Steinmann B, et al. Mass
 393 Spectrometric Analysis of Human Transferrin in Different Body Fluids. Clin Chem Lab
 394 Med. 2003 Jan 4;41(12):1580–8.
- 34. Coddeville B, Carchon H, Jaeken J, Briand G, Spik G. Determination of glycan structures
 and molecular masses of the glycovariants of serum transferrin from a patient with
 carbohydrate deficient syndrome type II. Glycoconj J. 1998;15(3):265–73.
- 398 35. HYDRAGEL 6 B2 TRANSFERRIN(E) Kit Instruction Manual. Sebia; 2011.
- 36. Caslavska J, Lanz C, Burda P, Tobler M, Thormann W. Analysis of genetic variants of
 transferrin in human serum after desialylation by capillary zone electrophoresis and capillary
 isoelectric focusing. J Sep Sci. 2017 Jun;40(11):2488–97.
- 402 37. Lee PL, Halloran C, Trevino R, Felitti V, Beutler E. Human transferrin G277S mutation: a
 403 risk factor for iron deficiency anaemia: Transferrin G277S Mutation and Anaemia. Br J
 404 Haematol. 2001 Nov;115(2):329–33.

- 405 38. Pang H, Koda Y, Soejima M, Kimura H. Identification of a mutation (A1879G) of transferrin
 406 from cDNA prepared from peripheral blood cells. Ann Hum Genet. 1998 May;62(3):271–4.
- 407 39. Evans RW, Crawley JB, Garratt RC, Grossmann JG, Neu M, Aitken A, et al.
- 408 Characterization and Structural Analysis of a Functional Human Serum Transferrin Variant
- and Implications for Receptor Recognition. Biochemistry. 1994 Oct 18;33(41):12512–20.

411 Tables

412

Table 1. The MPIE-ESI-MS results of 12 secretion samples from patients suspected of CSF leak.

	β1	-Tf	β2-Tf		
Secretion Sample	Detected?	Measured Molecular Mass	Detected?	Measured Molecular Mass	
Positive Sample 1	Yes	79554.50 Da	Yes	78008.42 Da	
Positive Sample 2	Yes	79554.79 Da	Yes	78008.60 Da	
Positive Sample 3	Yes	79554.75 Da	Yes	78008.83 Da	
Positive Sample 4	Yes	79554.04 Da	Yes	78008.68 Da	
Positive Sample 5	Yes	79554.77 Da	Yes	78008.03 Da	
Negative Sample 1	Yes	79554.29 Da	No	/	
Negative Sample 2	Yes	79554.80 Da	No	/	
Negative Sample 3	Yes	79554.81 Da	No	/	
Negative Sample 4	No	/	No	/	
Negative Sample 5	No	/	No	/	
Negative Sample 6	Yes	79554.49 Da	No	/	
Negative Sample 7	Yes	79554.73 Da	No	/	

415 **Figure Captions**

416

417	Figure 1. (A) Experiment	workflow of	MPIE-ESI-MS f	or Tf analysis.	The MPIE-ESI-MS	results
-----	--------------	--------------	-------------	---------------	-----------------	-----------------	---------

- of (B) a serum sample, (C) a CSF sample, and (D) a secretion sample from a patient diagnosed of
- 419 CSF leak: HR-MS raw mass spectra (left) and deconvoluted mass spectra (right) of captured Tf
- 420 molecules, showing serum-type Tf in (B), and both serum-type Tf and brain-type Tf in (C) and

421 (D).

422

Figure 2. The MPIE-ESI-MS results of (A) the extract from the gel stripe of the β_1 -Tf band

region and (B) the extract from the gel stripe of the β_2 -Tf band region: HR-MS raw mass spectra

(left) and deconvoluted mass spectra (right) of captured Tf molecules, showing β_1 -Tf in (B) and

426 β_2 -Tf in (C).

427

Figure 3. (A) Primary structure of human transferrin, showing the sequence of 679 amino acids, 19 disulfide bonds, and 2 N-glycosylation sites. (B) N-glycan structures on β_1 -Tf (major serumtype Tf) and β_2 -Tf (major brain-type Tf), confirmed by comparing the theoretical molecular masses of the Tf glycoforms with the measured molecular masses in Figure 1, Figure 2, and

432 Table 1.



Mass

(D)

Figure 2



Figure 3

(A) VPDKTVRWQA VSEHEATKQQ SFRDHMKSVI PSDGPSVAQV KKASYLDQIR AIAANEADAV TLDAGLVYDA YLAPNNLKPV VAEFYGSKED PQTFYYAVAV VKKDSGFQMN QLRGKKSCHT GLGRSAGWNI PIGLLYQDLP EPRKPLEKAV ANFFSGSQAP QADGTDFPQLQQIQPQQQCS TLNQYFGYSG AFKQLKDGAG DVAFVKHSTI FENLANKADR DQYELLQLDN TRKPVDEYKDQHLAQVPSHT VVARSMGGKE DLIWELLNQA QEHFGKDKSK EFQLFSSPHG KDLLFKDSAH GFLKVPPRMD AKMYLGYEYV TAIRNLREGT QPEAPTDEQK PVKWQALSHH ERLKQDEWSV NSVGKIEQVS AETTEDQIAK IMNGEADAMS LDGGFVYIAG KQGLVPVLAE NYNKSDNQED TPEAGYFAVA VVKKSASDLT WDNLKGKKSQ HTAVGRTAGW NIPMGLLYNK INHQRFDEFF SEGQAPGSKK DSSLQKLQMG SGLNLQEPNN KEGYYGYTGA FRQLVEKGDV AFVKHQTVPQ NTGGKNPDPW AKNLNEKDYE LLQLDGTRKP VEEYANQHLA RAPNHAVVTR KDKEAQVHKI LRQQQHLFGS NVTDQSGNFQ LFRSETKDLL FRDDTVQLAK LHDRNTYEKY LGEEYVKAVG NLRKQSTSSL LEAQTFRRP

Primary Structure of Human Transferrin: 679 AA, 19 Disulfide Bonds (Orange Label), 2 N-Glycosylation Sites (Blue Label)



Theoretical Molecular Mass: 79554.71 Da

Theoretical Molecular Mass: 78008.35 Da

Measured Molecular Mass: 79554.04 Da – 79554.81 Da Measured Molecular Mass: 78008.03 Da – 78008.83 Da